Matches in SemOpenAlex for { <https://semopenalex.org/work/W2571255963> ?p ?o ?g. }
Showing items 1 to 100 of
100
with 100 items per page.
- W2571255963 abstract "Abstract Idarubicin (IDA) is one of the key drugs for treating hematological malignancies. Severe myelosuppression is one of the major adverse events of IDA. Interestingly, when IDA is administered in 2 consecutive courses of therapy, IDA tends to exert a stronger bone marrow suppressive effect in the second course compared with the first course while other anthracyclines such as daunorubicin tend to milder suppressive effect in the second course compared with the first course (Wiernik PH et al, Blood, 1992). In order to clarify this unique characteristics, in vivo and in vitro studies regarding the pharmacokinetic behavior were performed. When RLN-B2 (a rat liver cell line) was precultured in the presence of IDA, higher carbonyl reducing enzymes (CREs) activity was observed compared with non-precultured cells, suggesting the anthracycline-reducing enzymes was induced in the cells incubated in the presence of IDA. We examined the in vivo effects of IDA administration on the induction of CREs and subsequent enhanced formation of the 13-OH metabolite, idarubicinol (IDAol) which is more active compared with IDA and has a remarkably long half-life in the blood. The rats (F344) preadministered IDA showed higher enzymatic activity than that from non-preadministered rats (p < 0.05). At 4 hours after IDA administration, the production of IDAol was facilitated in the preadministered group compared with the non preadministered group (p < 0.05). Clinically, the duration of leucopenia was compared between IDA and mitoxantrone, an CREs independent anthraquinone, in combination with enocytabine, 6-mercaptopurine and etoposide. In 2 consecutive therapy, namely remission-induction and first consolidation therapy, in 30 cases of acute myelogenous leukemias, the duration of leucopenia was substantially equal in IDA group while it was substantially shorter in consolidation therapy compared with induction therapy in mitoxantrone group. These results suggest that CREs was induced by IDA pretreatment in vitro and in vivo, resulting in increased IDAol, which could potentiate the myelosuppressive and probably antitumor effects of IDA in contrast to other anthracyclines. This unique PK/PD characteristics of pharmacokinetic self-potentiation could be important in the safe and effective use of IDA in the therapy for hematological malignancies." @default.
- W2571255963 created "2017-01-13" @default.
- W2571255963 creator A5005581117 @default.
- W2571255963 creator A5011340584 @default.
- W2571255963 creator A5018474376 @default.
- W2571255963 creator A5022142826 @default.
- W2571255963 creator A5022837694 @default.
- W2571255963 creator A5028349481 @default.
- W2571255963 creator A5041691581 @default.
- W2571255963 creator A5054372643 @default.
- W2571255963 creator A5057744038 @default.
- W2571255963 creator A5060744842 @default.
- W2571255963 creator A5063000058 @default.
- W2571255963 creator A5077635586 @default.
- W2571255963 date "2008-11-16" @default.
- W2571255963 modified "2023-09-30" @default.
- W2571255963 title "Unique Pharmacokinetic Self-Potentiation of Idarubicin through Induction of Carbonyl Reducing Enzymes in Contrast to Other Anthracyclines, Pharmacologic and Clinical Study" @default.
- W2571255963 doi "https://doi.org/10.1182/blood.v112.11.4025.4025" @default.
- W2571255963 hasPublicationYear "2008" @default.
- W2571255963 type Work @default.
- W2571255963 sameAs 2571255963 @default.
- W2571255963 citedByCount "0" @default.
- W2571255963 crossrefType "journal-article" @default.
- W2571255963 hasAuthorship W2571255963A5005581117 @default.
- W2571255963 hasAuthorship W2571255963A5011340584 @default.
- W2571255963 hasAuthorship W2571255963A5018474376 @default.
- W2571255963 hasAuthorship W2571255963A5022142826 @default.
- W2571255963 hasAuthorship W2571255963A5022837694 @default.
- W2571255963 hasAuthorship W2571255963A5028349481 @default.
- W2571255963 hasAuthorship W2571255963A5041691581 @default.
- W2571255963 hasAuthorship W2571255963A5054372643 @default.
- W2571255963 hasAuthorship W2571255963A5057744038 @default.
- W2571255963 hasAuthorship W2571255963A5060744842 @default.
- W2571255963 hasAuthorship W2571255963A5063000058 @default.
- W2571255963 hasAuthorship W2571255963A5077635586 @default.
- W2571255963 hasConcept C112705442 @default.
- W2571255963 hasConcept C121608353 @default.
- W2571255963 hasConcept C126322002 @default.
- W2571255963 hasConcept C149151106 @default.
- W2571255963 hasConcept C150903083 @default.
- W2571255963 hasConcept C181199279 @default.
- W2571255963 hasConcept C185592680 @default.
- W2571255963 hasConcept C207001950 @default.
- W2571255963 hasConcept C2776802502 @default.
- W2571255963 hasConcept C2777477808 @default.
- W2571255963 hasConcept C2778041864 @default.
- W2571255963 hasConcept C2778461978 @default.
- W2571255963 hasConcept C2779117419 @default.
- W2571255963 hasConcept C2781021840 @default.
- W2571255963 hasConcept C530470458 @default.
- W2571255963 hasConcept C55493867 @default.
- W2571255963 hasConcept C71924100 @default.
- W2571255963 hasConcept C86803240 @default.
- W2571255963 hasConcept C98274493 @default.
- W2571255963 hasConceptScore W2571255963C112705442 @default.
- W2571255963 hasConceptScore W2571255963C121608353 @default.
- W2571255963 hasConceptScore W2571255963C126322002 @default.
- W2571255963 hasConceptScore W2571255963C149151106 @default.
- W2571255963 hasConceptScore W2571255963C150903083 @default.
- W2571255963 hasConceptScore W2571255963C181199279 @default.
- W2571255963 hasConceptScore W2571255963C185592680 @default.
- W2571255963 hasConceptScore W2571255963C207001950 @default.
- W2571255963 hasConceptScore W2571255963C2776802502 @default.
- W2571255963 hasConceptScore W2571255963C2777477808 @default.
- W2571255963 hasConceptScore W2571255963C2778041864 @default.
- W2571255963 hasConceptScore W2571255963C2778461978 @default.
- W2571255963 hasConceptScore W2571255963C2779117419 @default.
- W2571255963 hasConceptScore W2571255963C2781021840 @default.
- W2571255963 hasConceptScore W2571255963C530470458 @default.
- W2571255963 hasConceptScore W2571255963C55493867 @default.
- W2571255963 hasConceptScore W2571255963C71924100 @default.
- W2571255963 hasConceptScore W2571255963C86803240 @default.
- W2571255963 hasConceptScore W2571255963C98274493 @default.
- W2571255963 hasLocation W25712559631 @default.
- W2571255963 hasOpenAccess W2571255963 @default.
- W2571255963 hasPrimaryLocation W25712559631 @default.
- W2571255963 hasRelatedWork W1492993712 @default.
- W2571255963 hasRelatedWork W153446213 @default.
- W2571255963 hasRelatedWork W1642110092 @default.
- W2571255963 hasRelatedWork W1964339593 @default.
- W2571255963 hasRelatedWork W2005926352 @default.
- W2571255963 hasRelatedWork W2019377094 @default.
- W2571255963 hasRelatedWork W2020509920 @default.
- W2571255963 hasRelatedWork W2085373537 @default.
- W2571255963 hasRelatedWork W2145128878 @default.
- W2571255963 hasRelatedWork W2145364998 @default.
- W2571255963 hasRelatedWork W2396149682 @default.
- W2571255963 hasRelatedWork W2397136069 @default.
- W2571255963 hasRelatedWork W2397193730 @default.
- W2571255963 hasRelatedWork W2407341673 @default.
- W2571255963 hasRelatedWork W2411115157 @default.
- W2571255963 hasRelatedWork W2411678575 @default.
- W2571255963 hasRelatedWork W2444268969 @default.
- W2571255963 hasRelatedWork W2891382926 @default.
- W2571255963 hasRelatedWork W2991275274 @default.
- W2571255963 hasRelatedWork W194140182 @default.
- W2571255963 isParatext "false" @default.
- W2571255963 isRetracted "false" @default.
- W2571255963 magId "2571255963" @default.
- W2571255963 workType "article" @default.